Detection of IDH2 Mutations and Monitoring Molecular Residual Disease in Patients With AML

Plain-language summary

This study evaluates the detection of IDH2 gene mutations and the monitoring of remaining disease at the molecular level (residual disease) in patients with acute myeloid leukemia (AML). It enrolled patients aged 20 and older who had been diagnosed with AML. This was a non-phase study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Chang Gung Memorial Hospital

Start date

3/1/2017

Estimated completion

7/31/2023

Countries

Taiwan

Related genes

Locations

• Taoyuan, Taiwan

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patients diagnosed with AML, age ≥ 20 years, and are willing to sign the informed consent

Exclusion Criteria:

* Not AML patients
* Patients diagnosed with AML but age \< 20 years